Background: The predisposition for obesity is suggested to originate in the prenatal period. Prenatal markers are needed to identify foetuses at risk for neonatal adiposity, as early marker of childhood obesity.
Introduction
The increasing prevalence of childhood obesity and its long-term health consequences leads to higher disease burden and healthcare costs already in early life (1, 2) . Lifestyle programs and interventions focusing on secondary prevention of childhood obesity have limited effects as the predisposition of obesity is suggested to originate in the periconceptional and prenatal periods (3, 4) . Prenatal markers of neonatal adiposity, considered a proxy of childhood obesity, are needed to predict the risk for neonatal adiposity and to monitor the effect of future prenatal prevention strategies for childhood obesity.
Previous studies have assessed the use of prenatal imaging as markers for neonatal adiposity (5) . Standard obstetrical two-dimensional biometric measures, such as estimated foetal weight, do not predict neonatal adiposity well (6) (7) (8) . A promising three-dimensional ultrasound (3D US) marker is fractional thigh volume (TVol) (7) . In the third trimester of pregnancy, this soft tissue marker is highly associated with neonatal percentage fat mass (7, 9) . To the best of our knowledge, the usefulness of earlier TVol measurement or TVol measured serially has not yet been studied. As foetal fat accumulation increases exponentially in the third trimester, TVol may be most informative in late pregnancy (10) . On the other hand, both 3D US scanning and TVol measurements are technically easier to perform earlier in pregnancy, and early measurements provide a longer timeframe for prevention strategies.
The primary aim of our study was to assess the association between TVol at different time points during the second half of pregnancy and neonatal adiposity. The secondary aim was to evaluate the association between TVol growth, based on serial measurements, and neonatal adiposity. We hypothesized that TVol is associated with neonatal percentage fat mass from mid-gestation onward and that the association between TVol growth and neonatal percentage fat mass is stronger than the association between single TVol measurements and neonatal percentage fat mass.
Methods
This study was embedded in the ongoing Rotterdam Periconceptional Cohort study (11) . Between November 2013 and July 2015, we invited women with an ongoing singleton pregnancy for prenatal 3D US examinations in the second and third trimesters of pregnancy and for cranial ultrasounds in the neonatal period. Between September 2014 and September 2016, body composition (BC) measurement was added to the postnatal follow-up visit. For the present analysis, we selected infants who were term born (≥37 weeks of gestation at birth), without congenital anomalies (EUROCAT criteria) and who had a BC measurement at the postnatal visit (12). All participating women and their partners gave written informed consent for both the Periconceptional Cohort study and the follow-up study. 
Prenatal scanning
Serial 3D US examinations were performed at 22, 26 and 32 weeks of gestation by a certified sonographer (I.K.) by using the Voluson E8 system (GE Medical Systems, Zipf, Australia) with a 1-7 MHz transabdominal transducer. Standard 2D biometric measurements were performed during the examinations. 3D volumes of the foetal thigh were obtained in the standard acquisition plane for femur diaphysis length measurement (13) . TVol (cm 3 ) was measured offline by one operator (J.R.) by using validated commercially available 3D software (4DView, version 5.0 or higher, GE Medical Systems). Volume measurement of the foetal thigh is based on 50% of the femoral diaphysis length. Five equidistant axial limb slices are shown by the software and are traced manually for each image slice. TVol is calculated automatically after tracing five slices (Fig. S1) (7) . As there is no evidence for length or volume differences between the left and right femur, measurements were performed on the thigh closest to the transducer. TVol measurements were performed in triplicate on each scan. If the smallest and largest TVol measurement differed more than 10%, a fourth measurement was performed. Hereafter, the outlier of the four measurements was removed. The mean of the three measurements was used in the analyses. 3D scans of very low quality, with severe movement artefacts or an inadequate sweep angle, were excluded.
We performed reliability analyses of TVol in this cohort by having TVol measurements of 30 randomly selected scans repeated by a second operator (I.K.). The analyses showed excellent intraobserver and interobserver reliability (intraclass correlation coefficients above 0.9).
Outcome measure
The outcome measure was neonatal body fat as percentage of total body weight (%BF), obtained via air-displacement plethysmography (PEA POD®, COSMED). This validated method calculates the absolute fat mass and fat free mass by direct measurement of body volume and body mass, based on the whole body densitometry principle (14, 15) . BC measurements were planned in the early neonatal period, between 42 +0 and 42 +6 -week postmenstrual age, independent of gestational age (GA) at birth. After having been trained by a dedicated research team, J.R. performed all BC measurements by using a standardized protocol.
Data collection
Maternal, obstetrical and neonatal outcome data were collected from questionnaires at enrolment, at 24 weeks of gestation and after birth (11) . Postnatal data included gender, GA at birth and birth weight.
Birth weight z scores corrected for GA and gender were calculated by using Fenton growth data (16) .
GA was calculated during the routine clinical intake visit, by using crown-rump length as dating measure for spontaneous pregnancies (17) . In pregnancies conceived through assisted reproductive technologies, dating was based on the date of oocyte retrieval, embryo transfer or insemination date, depending on the method of assisted reproductive technology. We defined foetal growth restriction (FGR) as estimated foetal weight or abdominal circumference below the fifth percentile (18, 19) . Being small for GA (SGA) at birth was defined as birth weight below the fifth percentile for GA.
There were neither missing covariates nor missing outcome data. As we assume that the missing foetal US data were missing at random, and linear mixed models make optimal use of all available data points, imputation was not needed (20) .
Statistical analyses
First, the association between TVol and neonatal fat mass was estimated for each measurement separately, i.e. 22, 26 and 32 weeks of gestation (cross-sectional analyses). Second, individual TVol growth trajectories were created to assess the association between TVol growth and neonatal fat mass (longitudinal analyses). All associations were explored in two models: a basic (model 1) and fully adjusted (model 2) model.
Cross-sectional analyses: In model 1, we adjusted for GA at moment of foetal 3D US examination and GA at postnatal BC measurement. Model 2 included the covariates of model 1 plus a predefined set of covariates based on plausible biological effects and existing literature including gender, parity, maternal age, prepregnancy BMI and smoking during pregnancy. The residuals of the linear regression analyses were approximately normally distributed.
Longitudinal analyses: Regression analyses on growth trajectories of TVol between 22 and 32 weeks of gestation and neonatal %BF were performed in two steps. First, a linear mixed model was estimated with the cube root of TVol as the response and GA at 3D US examination as covariate. The cube root transformation was opted for, as this made the residuals approximately homoscedastic and the relationship with GA approximately linear. The intercept and the GA were entered as random (i.e. subject specific) effects, providing individual intercepts and slopes for each foetus. The origin of the GA scale was placed at 160 days (baseline TVol size), and the TVol slope was measured as the increase in the cube root of TVol between 160 and 220 days (Δ TVol ) to aid interpretation and break the strong correlation between the two random effects. The subject-specific random effects were used as covariates in the second step in a linear regression model with %BF as outcome. In the second step, a basic and a complex model were applied. For the longitudinal analyses, model 1 included only GA at postnatal BC measurement. Model 2 included the covariates of model 1 plus the covariates included in model 2 of the single measurements.
To compare the predictive ability of the longitudinal model with the models by using single measurements, we used leave-one-out crossvalidation. For this, we deleted a single subject from the dataset on which we estimated our model and used this model to predict the outcome from the subject we deleted. This was carried out for all subjects. For the longitudinal model, this required computing the best linear unbiased predictions. The models were then compared by using the root mean square error (RMSE) to select the model with the highest predictive value (lowest RMSE).
Sensitivity analyses: In a tertiary hospital-based population, cases of pathologic foetal growth patterns are likely oversampled, which may influence the results. We therefore a priori-planned sensitivity analyses with exclusion of those foetuses with FGR and infants who were SGA at birth, applying the same models as in the primary analyses.
The data are presented as number (percentage) or median (interquartile range). A two-tailed p value of <0.05 was considered statistically significant. Data were analysed by using SPSS package 21.0 (IBM SPSS Statistics, Armonk, NY) and R (R: A language and Environment for Statistical Computing, version 3.1.3, 2015 for Windows, R Core Team, Vienna, Austria).
Results
Postnatal BC measurement was available for 99 infants during the study period. BC measurement was not successful in eight infants because of logistic or child-related reasons (i.e. crying), and six parents gave no consent. Six infants were born prematurely, and therefore excluded. The baseline characteristics of the79 mother-child pairs included are presented in Table 1 .
In total, 229 3D US examinations were performed of which 37 scans, equally distributed over the three time points, were not usable for TVol measurement, resulting in 192 TVol measurements. Standard foetal biometry data are presented in 
Cross-sectional analysis
Both models showed a statistically significant negative association between TVol at 22 weeks of gestation and neonatal %BF. The explained variance was 21% in model 1 and 31% in model 2. None of the models showed a significant association between TVol measured at 26 or 32 weeks of gestation and neonatal %BF (Table 3) .
Longitudinal analysis
Both models showed a statistically significant negative association between TVol growth and neonatal %BF, explained by baseline TVol size and not by increase in TVol between 22 and 32 weeks of gestation (Δ TVol ). The explained variance was 11% in model 1 and 18% in model 2 (Table 3) .
Root mean square error
Comparison of the predictive ability of the different models showed the lowest (most optimal) RMSE for the model at 22 weeks of gestation (RMSE 4.11). The RMSEs of the models at 26 and 32 weeks of gestation were respectively 4.48 and 4.38, and of the longitudinal model 4.29.
Sensitivity analysis
The sensitivity analyses were performed in infants with normal foetal growth (n = 73), by excluding those with FGR (n = 1), SGA (n = 3) or both (n = 2). Again, both models showed a statistically significant negative association between TVol at 22 weeks of gestation and neonatal %BF. TVols at 26 and 32 weeks were not significantly associated with %BF. The sensitivity analyses for TVol growth also showed a negative association, again explained by baseline TVol size and not by Δ TVol (Table S1 ).
Discussion
In this prospective perinatal cohort study, we evaluated the use of foetal fractional TVol measured from mid-gestation onward as marker of neonatal adiposity. A statistically significant association between TVol and neonatal %BF was found at 22 weeks of gestation. This finding confirms our hypothesis that TVol in mid-gestation might be useful to predict neonatal adiposity. We did not observe a significant association at 26 and 32 weeks of gestation. The longitudinal analyses of TVol growth showed a less strong association with neonatal %BF than TVol at 22 weeks of gestation, negating our second hypothesis.
We are the first to report that TVol at 22 weeks is negatively associated with neonatal %BF (i.e. a lower TVol is associated with a higher neonatal %BF). Future studies should confirm this finding. To understand this, at first glance on paradoxical finding, one should keep in mind the physiological growth pattern of a foetus. In early pregnancy, foetal growth only consists of lean mass, while from 28 weeks of gestation onward, foetal growth increasingly consists of fat mass (10) . Thus, extrapolating overall foetal growth to the foetal thigh TVol in mid-gestation solely measures lean mass, while at the end of pregnancy, it measures both fat and lean mass. The used measure for adiposity, %FM, is defined as absolute fat mass divided by total body weight (sum of fat and lean mass). An increased %FM can thus be the result of either a decreased absolute lean mass or an increased absolute fat mass; it is not necessarily contributed to fat mass alone.
In literature, it has been described that low birth weight and SGA infants carry a higher risk for obesity and cardiovascular risk factors (21) . Our findings confirm the results of these studies, but the underlying mechanisms are not fully unravelled yet. The validity of our finding is supported by the sensitivity analysis, showing an even stronger association in foetuses with normal growth.
To gain more insight in the underlying mechanism, we performed a post hoc analysis on the association between TVol at 22 weeks and the absolute amounts of neonatal fat and lean mass. We observed a negative association with absolute fat mass and no association with lean mass, indicating that a lower TVol is associated with a higher absolute fat mass in the neonatal period. This suggests that in foetuses with low lean mass in early pregnancy, it is fat accumulation that explains the higher neonatal %BF.
The clinical implications of this association, and of increased neonatal adiposity, are unclear. Although the effect size seems large (+1.6 %BF (≈+1/2 SD %FM) per cm 3 increase in TVol), the effect is limited due to the small absolute variance in TVol at 22 weeks (Table 2) . Altogether, our data suggest that effects of cardiometabolic programming are already present and detectable in utero.
The potential of foetal TVol as predictor of neonatal adiposity in mid-gestation has not been described before as previous studies assessed the use of TVol after 27 weeks of gestation. They all used airdisplacement plethysmography for BC measurement, similar to our method. In 2009, Lee et al. were the first to report a positive association between TVol, measured shortly before delivery, and neonatal %BF (7) . Later, O'Connor et al. did not find any significant correlation between TVol measured at 28, 33 and 37 weeks of gestation and neonatal %BF, which corresponds with our findings (22) . The most recently published study by Moore et al. found no association at 36 weeks, but did find a strong positive association between TVol measured at 28 weeks of gestation and neonatal %BF (9) . Despite their sample size of only 32 mother-child pairs, they estimated an explained variance of almost 70% (effect size not reported). Such a strong association at this time point has not been described before and is in contrast to our findings and those of O'Connor et al. As they do not speculate on the underlying absolute fat and lean masses, it is difficult to interpret their findings. Still, differences in study design and study population may explain the contrasting findings.
We consider the prospective design with serial standardized measurements and the longitudinal analyses of the serial data the main strengths of our study. Another strength is that both prenatal and postnatal measurements were performed around the same postconceptional age, allowing for better cross-sectional comparison. Of interest is the relatively high %BF in our population compared with data from previous studies (6, 23, 24) . This is likely explained by timing of BC measurement between 42 and 43 weeks of gestation that includes the period of physiological increase in body fat in the first weeks after term age (25) . Interpretation of fat mass measured sooner after birth is complicated by the initial physiological process of weight and fat loss and regain of weight thereafter in the first days after birth (8, 26) . In an additional post hoc analysis, we studied the effect of variation in postnatal age at BC measurement (median 25, range 7-40 days) by adding this term to the final adjusted models. No improvement of model fit for all analyses suggests that differences in postnatal age did not importantly influence our results (data not shown). Breastfeeding was not taken into account in the analyses because misclassification is likely in our partially breastfed population.
Related to the design and the sample size of our study, we face some limitations. We did not perform 3D US after 32 weeks of gestation, which would have given us a more complete overview of the development of TVol and its association with neonatal adiposity. Moreover, larger studies are needed to determine the long-term consequences of increased fat accumulation in the prenatal and early postnatal period. The external validity may be reduced as the women studied were relatively old, highly educated and mainly of Caucasian ethnicity. Moreover, our tertiary hospital population included high numbers of in vitro insemination/intracytoplasmic sperm injection pregnancies (Table 1) .
We believe that TVol measurement is easy to perform in 4DView, but we also experienced the technical limitations described earlier (7) We expect that the ongoing development of automated image analysis tools with higher precision and faster calculations will increase the clinical feasibility of TVol measurement as an additional bedsideavailable technique for monitoring of foetal growth (27) .
In the future, TVol might be used in prediction models for neonatal adiposity, including other relevant predictors such as maternal BMI (5) . TVol might also be a useful tool to evaluate the effect of interventions and may help to unravel the complex interaction between environmental risk factors and recently identified genetic risk factors for childhood obesity (28) 
Conclusion
This prospective perinatal study showed that foetal TVol in mid-gestation is a promising 3D US soft tissue marker for prediction of neonatal adiposity and for monitoring of effects of prenatal prevention strategies for childhood obesity. Serial assessment between 22 and 32 weeks of gestation showed little additional value for prediction of neonatal adiposity when compared with single TVol measurement at 22 weeks.
